GLP-1 Prior Authorization Guide 2026: How to Get Approved

Quick answer: What is GLP-1 prior authorization?

Prior authorization is a process where your insurance company requires your healthcare provider to prove medical necessity before they'll cover a GLP-1 medication. For Wegovy, Zepbound, Mounjaro, or Foundayo, your provider must submit documentation showing your BMI, weight-related conditions, and prior weight loss attempts. The process typically takes 3-14 business days. Approval is not guaranteed, but proper documentation significantly improves your chances.

If you want to skip the insurance process entirely, telehealth providers offer cash-pay GLP-1 programs from $99/month with no prior authorization required.

Step-by-step prior authorization process

1. Verify coverage: Contact your insurance to confirm whether your plan covers GLP-1 medications and what the prior authorization requirements are. Ask about formulary tier, copay, and step therapy requirements.
2. Schedule a provider visit: See your doctor or a telehealth provider to discuss GLP-1 treatment. Your provider will document your BMI, weight-related conditions, and medical history.
3. Provider submits prior auth: Your provider's office submits the prior authorization request with supporting documentation to your insurance company.
4. Insurance review: The insurance company reviews the submission. This typically takes 3-14 business days (up to 15 days for standard, 72 hours for expedited).
5. Decision: You'll receive an approval or denial. If approved, you can fill your prescription at the approved copay. If denied, you can appeal — see our insurance appeal guide.

Required documentation for prior authorization

Your provider will need to submit the following documentation:

Common reasons for prior auth denial

• Plan exclusion: The plan simply doesn't cover weight loss medications (even with prior auth)
• Step therapy not met: Insurance requires you to try other medications first (e.g., metformin, phentermine) before GLP-1s
• Insufficient documentation: Missing BMI, diagnosis codes, or prior weight loss attempts
• Off-label prescribing: Medication prescribed for a non-FDA-approved indication
• Missing medical necessity letter: Provider didn't include a clinical justification

If denied, see our insurance appeal guide for how to overturn the decision.

Tips to improve prior auth approval odds

• Be thorough: Ensure your provider submits all required documentation the first time
• Document everything: Prior weight loss attempts, diet programs, exercise regimens — all of it
• Cite FDA approval: Make sure the prescription matches the FDA-approved indication (Wegovy for weight management, not Ozempic)
• Emphasize comorbidities: List all weight-related conditions — hypertension, sleep apnea, fatty liver, etc.
• Reference clinical guidelines: The 2026 AHA/ACC/ADA/ASN CKM Syndrome Guideline supports GLP-1 use
• Request expedited review: If you have urgent cardiovascular or metabolic risk, ask for a 72-hour expedited review
• Follow up: Call your insurance every 3-5 days to check the status of your prior auth

Alternatives to prior authorization

If you don't want to wait for prior authorization or your plan doesn't cover GLP-1s, you have several alternatives:

• Manufacturer savings card: $25/month with commercial insurance — see our PAP guide
• NovoCare self-pay: Wegovy pill from $149/month — see our NovoCare guide
• LillyDirect self-pay: Zepbound from $299/month — see our LillyDirect guide
• Compounded GLP-1: From $99/month through telehealth — see cheapest options
• Patient assistance program: Free medication for low-income patients — see our PAP guide

The bottom line

Prior authorization is a common hurdle for GLP-1 coverage, but it's surmountable with proper documentation and persistence. Work closely with your provider to submit a complete package, follow up regularly, and be prepared to appeal if denied. If you need treatment immediately or want to avoid the insurance process, cash-pay options from $99/month are available through telehealth providers.